Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials
- PMID: 24419108
- DOI: 10.1200/JCO.2013.51.2186
Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials
Abstract
Purpose: To analyze recurrence patterns in patients with cancer of the esophagus or gastroesophageal junction treated with either preoperative chemoradiotherapy (CRT) plus surgery or surgery alone.
Patients and methods: Recurrence pattern was analyzed in patients from the previously published CROSS I and II trials in relation to radiation target volumes. CRT consisted of five weekly courses of paclitaxel and carboplatin combined with a concurrent radiation dose of 41.4 Gy in 1.8-Gy fractions to the tumor and pathologic lymph nodes with margin.
Results: Of the 422 patients included from 2001 to 2008, 418 were available for analysis. Histology was mostly adenocarcinoma (75%). Of the 374 patients who underwent resection, 86% were allocated to surgery and 92% to CRT plus surgery. On January 1, 2011, after a minimum follow-up of 24 months (median, 45 months), the overall recurrence rate in the surgery arm was 58% versus 35% in the CRT plus surgery arm. Preoperative CRT reduced locoregional recurrence (LRR) from 34% to 14% (P < .001) and peritoneal carcinomatosis from 14% to 4% (P < .001). There was a small but significant effect on hematogenous dissemination in favor of the CRT group (35% v 29%; P = .025). LRR occurred in 5% within the target volume, in 2% in the margins, and in 6% outside the radiation target volume. In 1%, the exact site in relation to the target volume was unclear. Only 1% had an isolated infield recurrence after CRT plus surgery.
Conclusion: Preoperative CRT in patients with esophageal cancer reduced LRR and peritoneal carcinomatosis. Recurrence within the radiation target volume occurred in only 5%, mostly combined with outfield failures.
Comment in
-
Combination chemoradiation therapy: the whole is more than the sum of the parts.J Clin Oncol. 2014 Feb 10;32(5):367-9. doi: 10.1200/JCO.2013.54.3108. Epub 2014 Jan 13. J Clin Oncol. 2014. PMID: 24419110 No abstract available.
-
[Comparison of recurrence patterns in esophageal carcinoma after surgery alone and surgery after neoadjuvant chemoradiotherapy: a secondary analysis of the CROSS study].Strahlenther Onkol. 2014 Jul;190(7):696-8. doi: 10.1007/s00066-014-0682-5. Strahlenther Onkol. 2014. PMID: 25061651 German. No abstract available.
-
Optimal management of esophageal adenocarcinoma: should we be CROSS?J Clin Oncol. 2014 Sep 20;32(27):3080-1. doi: 10.1200/JCO.2014.55.5243. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071100 No abstract available.
-
Reply to E. C. Smyth et al.J Clin Oncol. 2014 Sep 20;32(27):3082. doi: 10.1200/JCO.2014.56.3874. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071102 No abstract available.
-
Reply to E. C. Smyth et al.J Clin Oncol. 2014 Sep 20;32(27):3081-2. doi: 10.1200/JCO.2014.56.3866. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071131 No abstract available.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
